Characteristics of the included trials
| Author/ Year | Type of study (years) | Country | Jadad or NOS score | NO. pts | Histologi cal type | Median age (years) | Stage (FIGO) | ECCR1 assay | Cut-off for high expression | Positive(high) /negative(low) (NO.) | Treatment (predominant) | Median follow-up (months) | Out comes |
| Hasegawa/201115 | Retro (2000–2007) | Japan | ******* | 25 | AC:25 | 46 (30–67) | Ib–IIb | IHC | nuclear staining scores 4–6 【6.1-5】 | 5/20 | S±CCT/CCT&RT | NR | DFS, CP |
| Liang/201116 | Retro (NR) | Korea | ******* | 50 | SCC:50 | 54 (40–73) | II–III | IHC | H-score>1.5 (IRS) | 16/34 | CCCRT | 56.3 (8.1-103.5) | DSS, OS, CP, treatment response |
| Park/201117 | Retro (1999–2006) | Korea | ****** | 43 | SCC:36 Others:7 | 50 (36–78) | IIb | IHC | H-score>1.0 (IRS) | 34/9 | NACCT+S | 45.0 (6.0–139.0) | DFS, CP, treatment response |
| Bai/201218 | Retro (2009–2010) | China | ****** | 60 | SCC:60 | 53 (36–80) | II-III | RT-PCR | 0.0347 excission repair cross-complementation group one enzyme | 29/31 | CCCRT | NR | CP, treatment response |
| Doll/201312 | Retro/pro(1999–2004) | Canada | ******* | 264 | NR | 49 (NR) | I–IV | IHC | excission repair cross-complementation group one enzyme n/c ratio 1.43 | 132/132 | CCCRT | 54.0(3.8–110.4) | PFS, OS, CP |
| Muallem/201413 | Retro (2006–2012) | Germany | ******* | 112 | SCC:100 AC:12 | 44 (26–82) | Ib–IVa | IHC | H-score>1.5 (IRS) | 72/40 | CCCRT±S | NR | PFS, OS |
| Zwenger/201519 | Pro (1993–2007) | Argentina | 5 | 26 | SCC:26 | 43.5 (24–74) | IIb–IVa | IHC | H-score>0.5 (IRS) | 13/13 | CCCRT | 24.0 (1.2–220.8) | DFS, OS, CP, treatment response |
| Ryu/201711 | Retro (2004–2011) | Korea | ******* | 32 | SCC:24AC:3 Others:5 | 51(34–67) | NR | IHC | H-score>1.5 (IRS) | 13/19 | CCT | NR | PFS, OS, CP, treatment response |
AC, adenocarcinoma; CCCRT, cisplatin based concurrent chemoradiotherapy; CCT, cisplatin based chemotherapy; CP, clinicopathological parameters; DFS, disease free survival; IHC, immunohistochemistry; IRS, immunoreactive score; NACCT, neoadjuvant cisplatin based chemotherapy; NOS, Nottingham Ottawa Scale; NR, no report; OS, overall survival; PFS, progress free survival; RCT, randomised controlled trial; RT, radiotherapy; Retro, retrospective comparative study; S, surgery; SCC, squamous cell carcinoma; pts, patients.